Hemogenyx and Selexis agree to develop cell line for Hemogenyx's CDX bispecific antibody Jan. 13, 2022
Immix reports promising response rate with IMX-110 in first-line therapy-resistant STS mouse study Jan. 13, 2022
Lantern Pharma expands collaboration with NCI to support progression of LP-184 and LP-284 Jan. 13, 2022
RSS